<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230217</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5339</org_study_id>
    <nct_id>NCT00230217</nct_id>
    <nct_alias>NCT00086918</nct_alias>
    <nct_alias>NCT00247767</nct_alias>
  </id_info>
  <brief_title>Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy</brief_title>
  <official_title>Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center study with 2 arms. The primary objective is to assess the&#xD;
      response to treatment with rasburicase in 2 populations of adult and pediatric patients with&#xD;
      lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent,&#xD;
      and those not previously treated with a uricolytic agent at their first relapse or refractory&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, 2 arm, open-label study;&#xD;
&#xD;
        -  Arm A: Patients previously treated with a uricolytic agent;&#xD;
&#xD;
        -  Arm B: Patients not previously treated with a uricolytic agent.&#xD;
&#xD;
      Patients receive rasburicase for 5 days and begin chemotherapy 4-24 hours after the first&#xD;
      dose of rasburicase. Patients are followed at 14 and 35 days, at 3 and 6 months and every 6&#xD;
      months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive response based on plasma uric acid levels.</measure>
    <time_frame>up to 48 hours after last administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety assessment</measure>
  </secondary_outcome>
  <enrollment type="Actual">94</enrollment>
  <condition>Tumors</condition>
  <condition>Hyperuricemia</condition>
  <condition>Tumor Lysis Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasburicase (SR29142)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets one of the following risk criteria for tumor lysis syndrome (TLS):&#xD;
&#xD;
             A patient is at high risk for TLS if he/she presents with:&#xD;
&#xD;
               -  Hyperuricemia of malignancy (plasma uric acid &gt; 7.5 mg/dL);&#xD;
&#xD;
               -  A diagnosis of a very aggressive lymphoma/leukemia based on the Revised&#xD;
                  European-American Lymphoma (REAL) classification of lymphoma/leukemia;&#xD;
&#xD;
               -  Acute myeloid leukemia (AML);&#xD;
&#xD;
               -  Chronic myeloid leukemia (CML) in blast crisis; or&#xD;
&#xD;
               -  High grade myelodysplastic syndrome (refractory anemia with excess blast,&#xD;
                  refractory anemia with excess blast in transformation, or chronic myelomonocytic&#xD;
                  leukemia) only if they have &gt; 10% bone marrow blast and are given aggressive&#xD;
                  treatment similar to AML&#xD;
&#xD;
             A patient is at potential risk for TLS if he/she presents with:&#xD;
&#xD;
               -  A diagnosis of an aggressive lymphoma/leukemia based on the REAL classification&#xD;
                  of lymphoma/leukemia plus 1 or more of the following criteria:&#xD;
&#xD;
                    -  Lactate dehydrogenase (LDH) &gt; 2 x upper limit of normal (ULN)(IU/L)&#xD;
&#xD;
                    -  Stage III-IV disease&#xD;
&#xD;
                    -  Stage I-II disease with 1 lymph node/tumor &gt; 5 cm in diameter&#xD;
&#xD;
          2. Patients previously treated with a uricolytic agent or not at their first relapse or&#xD;
             refractory disease&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-3. ECOG equivalent&#xD;
             derived from Karnofsky performance scale 100-30 or Lansky performance score 100-30&#xD;
             (patients &lt; or = 16 years of age) may also be used.&#xD;
&#xD;
          4. Life expectancy &gt;3 months&#xD;
&#xD;
          5. Negative pregnancy test (females of child bearing potential) and use of effective&#xD;
             contraceptive method (both males and females). A pregnancy test may be performed on&#xD;
             serum or urine human chorionic gonadotropin (HCG).&#xD;
&#xD;
          6. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of established diagnosis of asthma or severe life-threatening atopic allergy&#xD;
&#xD;
          2. Hypersensitivity to uricases or any of the excipients&#xD;
&#xD;
          3. Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or history of&#xD;
             hemolysis indicative of G6PD deficiency&#xD;
&#xD;
          4. Pregnant or lactating&#xD;
&#xD;
          5. Concomitant treatment with any investigational drug&#xD;
&#xD;
          6. Planned treatment with rituximab&#xD;
&#xD;
          7. Receipt of rituximab within the 12 month period prior to study entry&#xD;
&#xD;
          8. Unwilling or unable to comply with the requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alta Bates Comprehensive Cancer Center</name>
      <address>
        <city>Berkley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center at Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma HSC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health Systems</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <last_update_submitted>March 27, 2009</last_update_submitted>
  <last_update_submitted_qc>March 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Relapse</keyword>
  <keyword>Refracturing</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

